Common and Low-Frequency Genetic Variants in the PCSK9 Locus Influence Circulating PCSK9 Levels

被引:55
作者
Chernogubova, Ekaterina [1 ]
Strawbridge, Rona [1 ]
Mahdessian, Hovsep [1 ]
Malarstig, Anders [1 ]
Krapivner, Sergey
Gigante, Bruna [2 ]
Hellenius, Mai-Lis [2 ]
de Faire, Ulf [2 ]
Franco-Cereceda, Anders [3 ]
Syvaenen, Ann-Christine [4 ]
Troutt, Jason S.
Konrad, Robert J. [5 ]
Eriksson, Per [1 ]
Hamsten, Anders [1 ]
van 't Hooft, Ferdinand M. [1 ]
机构
[1] Karolinska Inst, Cardiovasc Genet & Genom Grp, Atherosclerosis Res Unit, Dept Med Solna, Stockholm, Sweden
[2] Karolinska Inst, Div Cardiovasc Epidemiol, Inst Environm Med, Stockholm, Sweden
[3] Karolinska Inst, Cardiothorac Surg Unit, Dept Mol Med & Surg, Stockholm, Sweden
[4] Uppsala Univ, Mol Med Unit, Dept Med Sci, Uppsala, Sweden
[5] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA
基金
瑞典研究理事会;
关键词
dense mapping; genetic variants; genome-wide association study; low-density lipoprotein cholesterol; proprotein convertase subtilisin/kexin type 9; LIPOPROTEIN CHOLESTEROL LEVELS; CORONARY-ARTERY-DISEASE; PLASMA PCSK9; LDL CHOLESTEROL; SECRETED PCSK9; HEART-DISEASE; MOUSE-LIVER; RISK; MICE; DEGRADATION;
D O I
10.1161/ATVBAHA.111.240549
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective-Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a circulating protein that influences plasma low-density lipoprotein concentration and susceptibility to coronary heart disease. Circulating PCSK9 levels show considerable interindividual differences, but the factors responsible for this variation are largely unknown. Methods and Results-We analyzed circulating PCSK9 levels in 4 cohorts of healthy, middle-aged Swedes (n=5722) and found that PCSK9 levels varied over approximate to 50-fold range, showed a positive relationship with plasma low-density lipoprotein-cholesterol concentration, and were associated with plasma triglyceride, fibrinogen, insulin, and glucose concentrations. A genome-wide association study conducted in 2 cohorts (n=1215) failed to uncover common genetic variants robustly associated with variation in circulating PCSK9 level. As expected, the minor allele of the PCSK9 R46L variant was in all cohorts associated with reduced PCSK9 levels and decreased plasma low-density lipoprotein-cholesterol concentrations, but no relationship was observed with the plasma triglyceride concentration. Further mapping of the PCSK9 locus revealed a common polymorphism (rs2479415, minor allele frequency 43.9%), located approximate to 6 kb upstream from PCSK9, which is independently associated with increased circulating PCSK9 levels. Conclusion-Common and low-frequency genetic variants in the PCSK9 locus influence the pronounced interindividual variation in circulating PCSK9 levels in healthy, middle-aged white (predominantly Swedish) subjects. (Arterioscler Thromb Vasc Biol. 2012;32:1526-1534.)
引用
收藏
页码:1526 / +
页数:15
相关论文
共 50 条
  • [21] PCSK9 genetic (rs11591147) and epigenetic (DNA methylation) modifications associated with PCSK9 expression and serum proteins in CAD patients
    Shyamala, Nivas
    Gundapaneni, Kishore Kumar
    Galimudi, Rajesh Kumar
    Tupurani, Mohini Aiyengar
    Padala, Chiranjeevi
    Puranam, Kaushik
    Kupsal, Keerthi
    Kummari, Ramanjaneyulu
    Gantala, Srilatha Reddy
    Nallamala, Krishna Reddy
    Sahu, Sanjib K.
    Hanumanth, Surekha Rani
    [J]. JOURNAL OF GENE MEDICINE, 2021, 23 (08)
  • [22] Safety of PCSK9 inhibitors
    Grzesk, Grzegorz
    Dorota, Bednarska
    Wolowiec, Lukasz
    Wolowiec, Anna
    Osiak, Joanna
    Kozakiewicz, Mariusz
    Banach, Joanna
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2022, 156
  • [23] Heart to heart with PCSK9
    Chemello, Kevin
    Jaafar, Ali K.
    Lambert, Gilles
    [J]. EUROPEAN HEART JOURNAL, 2021, 42 (32) : 3091 - 3093
  • [24] Targeting PCSK9 for Hypercholesterolemia
    Norata, Giuseppe Danilo
    Tibolla, Gianpaolo
    Catapano, Alberico Luigi
    [J]. ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 54, 2014, 54 : 273 - 293
  • [25] PCSK9 in diabetic kidney disease
    Elewa, Usama
    Fernandez-Fernandez, Beatriz
    Mahillo-Fernandez, Ignacio
    Martin-Cleary, Catalina
    Belen Sanz, Ana
    Sanchez-Nino, Maria D.
    Ortiz, Alberto
    [J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2016, 46 (09) : 779 - 786
  • [26] The promises of PCSK9 inhibition
    Petrides, Francine
    Shearston, Kate
    Chatelais, Mathias
    Guilbaud, Florian
    Meilhac, Olivier
    Lambert, Gilles
    [J]. CURRENT OPINION IN LIPIDOLOGY, 2013, 24 (04) : 307 - 312
  • [27] PCSK9 in metabolism and diseases
    Ajoolabady, Amir
    Pratico, Domenico
    Mazidi, Mohsen
    Davies, Ian G.
    Lip, Gregory Y. H.
    Seidah, Nabil
    Libby, Peter
    Kroemer, Guido
    Ren, Jun
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 2025, 163
  • [28] PCSK9 Inhibition The Next Statin?
    Vogel, Robert A.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 59 (25) : 2354 - 2355
  • [29] The Evolving Future of PCSK9 Inhibitors
    Rosenson, Robert S.
    Hegele, Robert A.
    Fazio, Sergio
    Cannon, Christopher P.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 72 (03) : 314 - 329
  • [30] PCSK9 Association With Lipoprotein(a)
    Tavori, Hagai
    Christian, Devon
    Minnier, Jessica
    Plubell, Deanna
    Shapiro, Michael D.
    Yeang, Calvin
    Giunzioni, Ilaria
    Croyal, Mikael
    Duell, P. Barton
    Lambert, Gilles
    Tsimikas, Sotirios
    Fazio, Sergio
    [J]. CIRCULATION RESEARCH, 2016, 119 (01) : 29 - +